Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levodropropizine + chlorpheniramine maleate is a fixed-dose combination pharmaceutical product developed by Crest Lifesciences for the treatment of dry, irritating coughs and allergy-related respiratory symptoms. It consists of levodropropizine, a non-opioid antitussive that suppresses the cough reflex through central action in the medulla oblongata and peripheral effects, and chlorpheniramine maleate, a first-generation H1 receptor antagonist that competes with histamine to alleviate allergic reactions in the respiratory tract. The drug is formulated as a syrup and is approved for marketing in India, typically indicated for coughs associated with respiratory tract infections and allergies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levodropropizine + chlorpheniramine maleate.